Literature DB >> 20428930

Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Cuyue Tang1, Thomayant Prueksaritanont.   

Abstract

Animal models are used commonly in various stages of drug discovery and development to aid in the prospective assessment of drug-drug interaction (DDI) potential and the understanding of the underlying mechanism for DDI of a drug candidate. In vivo assessments in an appropriate animal model can be very valuable, when used in combination with in vitro systems, to help verify in vivo relevance of the in vitro animal-based results, and thus substantiate the extrapolation of in vitro human data to clinical outcomes. From a pharmacokinetic standpoint, a key consideration for rational selection of an animal model is based on broad similarities to humans in important physiological and biochemical parameters governing drug absorption, distribution, metabolism or excretion (ADME) processes in question for both the perpetrator and victim drugs. Equally critical are specific in vitro and/or in vivo experiments to demonstrate those similarities, usually both qualitative and quantitative, in the ADME properties/processes under investigation. In this review, theoretical basis and specific examples are presented to illustrate the utility of the animal models in assessing the potential and understanding the mechanisms of DDIs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428930     DOI: 10.1007/s11095-010-0157-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  103 in total

1.  Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450.

Authors:  Magang Shou; Ryan Norcross; Grit Sandig; Ping Lu; Yinghe Li; Yuh Lin; Qin Mei; A David Rodrigues; Thomas H Rushmore
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

2.  Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates.

Authors:  S V Mandlekar; A V Rose; G Cornelius; B Sleczka; C Caporuscio; J Wang; P H Marathe
Journal:  Xenobiotica       Date:  2007-09       Impact factor: 1.908

3.  Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.

Authors:  Miki Katoh; Naoto Suzuyama; Toshiyuki Takeuchi; Sumie Yoshitomi; Satoru Asahi; Tsuyoshi Yokoi
Journal:  J Pharm Sci       Date:  2006-12       Impact factor: 3.534

4.  The chimpanzee cytochrome P450 3A subfamily: Is our closest related species really that similar?

Authors:  Eric T Williams; Katherine R Schouest; Małgorzata Leyk; Henry W Strobel
Journal:  Comp Biochem Physiol Part D Genomics Proteomics       Date:  2007-01-26       Impact factor: 2.674

5.  Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism.

Authors:  Justine L Lam; Sarah B Shugarts; Hideaki Okochi; Leslie Z Benet
Journal:  J Pharmacol Exp Ther       Date:  2006-08-11       Impact factor: 4.030

Review 6.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction.

Authors:  Marcella Martignoni; Geny M M Groothuis; Ruben de Kanter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

Review 7.  Effects of drug transporters on volume of distribution.

Authors:  Anita Grover; Leslie Z Benet
Journal:  AAPS J       Date:  2009-04-28       Impact factor: 4.009

Review 8.  Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. evidence that the dog is not a relevant species for evaluation of human health risk.

Authors:  Charles Timchalk
Journal:  Toxicology       Date:  2004-07-15       Impact factor: 4.221

9.  Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver.

Authors:  Y Nishibe; M Wakabayashi; T Harauchi; K Ohno
Journal:  Xenobiotica       Date:  1998-06       Impact factor: 1.908

Review 10.  The complexities of hepatic drug transport: current knowledge and emerging concepts.

Authors:  Priyamvada Chandra; Kim L R Brouwer
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.580

View more
  7 in total

Review 1.  ADME of biologics-what have we learned from small molecules?

Authors:  Thomayant Prueksaritanont; Cuyue Tang
Journal:  AAPS J       Date:  2012-04-07       Impact factor: 4.009

Review 2.  Molecular mass spectrometry imaging in biomedical and life science research.

Authors:  Jaroslav Pól; Martin Strohalm; Vladimír Havlíček; Michael Volný
Journal:  Histochem Cell Biol       Date:  2010-10-28       Impact factor: 4.304

Review 3.  Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.

Authors:  Christopher R Jones; Oliver J D Hatley; Anna-Lena Ungell; Constanze Hilgendorf; Sheila Annie Peters; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-03-10       Impact factor: 4.009

4.  Solid dispersion tablets of breviscapine with polyvinylpyrrolidone K30 for improved dissolution and bioavailability to commercial breviscapine tablets in beagle dogs.

Authors:  Wenjuan Cong; Lan Shen; Desheng Xu; Lijie Zhao; Kefeng Ruan; Yi Feng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-09-06       Impact factor: 2.441

5.  Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel.

Authors:  Marion Paolini; Laurence Poul; Céline Berjaud; Matthieu Germain; Audrey Darmon; Maxime Bergère; Agnès Pottier; Laurent Levy; Eric Vibert
Journal:  Int J Nanomedicine       Date:  2017-08-02

6.  Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson's disease: a case control study.

Authors:  Muhammad Aslam; Nafees Ahmad; Jakob von Engelhardt; Mazhar Badshah; Rashda Abbasi; Aneesa Sultan; Kafaitullah Khan
Journal:  Genes Environ       Date:  2017-07-01

Review 7.  Engineering large animal models of human disease.

Authors:  C Bruce A Whitelaw; Timothy P Sheets; Simon G Lillico; Bhanu P Telugu
Journal:  J Pathol       Date:  2015-11-28       Impact factor: 7.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.